Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

← catalyst calendar

NCT05875974

Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.

Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
207actual
Sites
32
Countries
Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-07-27actualWhen the study began enrolling
Primary completion2025-03-13actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-03-13actualThe whole study's end, after follow-up
First posted2023-05-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-07-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Idiopathic Hypersomnia
  • Narcolepsy

Intervention

  • Drug: JZP258 (XYWAV)

Primary outcome

what the primary-completion date above is the date OF
Epworth Sleepiness Scale (ESS) Total Score in Participants With IH and Narcolepsy Treated With XYWAV
measured Baseline up to End of Treatment (approximately 10-36 weeks)

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed